2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2980

Inflammation As an Under-Recognized Cause of Ascending Aortic Aneurysms: A Single-Center Clinical and Pathological Study of 53 Cases over 6 Years
Abstract Number: 3090

Inflammation Detected with Modern Sensitive MRI Analysis Demonstrates That Therapeutic Response As Early As One Month Predicts 12-Month Radiographic Progression: Data from a Study Using Tofacitinib and Methotrexate in Early RA
Abstract Number: 2413

Inflammation Regulating microRNAs, Mir-146b, Mir-155 and Mir-192-5p Are Altered in Plasma and Synovial Fluid of Oligoarticular Juvenile Idiopathic Arthritis
Abstract Number: 1286

Inflammatory Activity of IgG4-Related Disease Lesions Assessed By Quantitative Positron Emission Tomography Correlates with Circulating Plasmablasts Levels
Abstract Number: 2166

Inflammatory Arthropathy and Hashimoto’s Thyroiditis: Prevalence and Associated Factors
Abstract Number: 3046

Inflammatory Pathways As Shared Molecular Targets Across ANCA-Associated Vasculitis and Nephrotic Syndrome
Abstract Number: 2288

Inflammatory Status and Serum Uric Acid Determine High-Density Lipoprotein Cholesterol Levels in a Non-Rheumatic Population
Abstract Number: 2481

Infliximab Low Levels at Early Stages Predict the Loss of Drug Levels and the Clinical Response at One Year of Treatment in Patients with Rheumatoid Arthritis
Abstract Number: 1122

Infliximab Suppresses the Monocyte Chemotaxis in Human TNF-Transgenic Mice
Abstract Number: 1683

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 3135

Influence of Baseline Magnetic Resonance Imaging Features on Outcomes of Operative and Non-Operative Treatment of Meniscal Tear in Patients ≥ 45
Abstract Number: 2224

Influence of Caffeine on Opioid Analgesics in Fibromyalgia
Abstract Number: 1649

Influence of Modifiable Risk Factors on the Response to MTX Alone in Early RA Patients
Abstract Number: 2307

Influence of Season and Residential Environment on Development of Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis with Interstitial Lung Disease
Abstract Number: 1809

Influence of Solar Radiation in Cutaneous Manifestations of Lupus: Data from the Gladel Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].